U.S. Markets closed
  • S&P 500

    3,271.03
    -119.65 (-3.53%)
     
  • Dow 30

    26,519.95
    -943.24 (-3.43%)
     
  • Nasdaq

    11,004.87
    -426.53 (-3.73%)
     
  • Russell 2000

    1,543.28
    -47.20 (-2.97%)
     
  • Crude Oil

    37.38
    -2.19 (-5.53%)
     
  • Gold

    1,877.40
    -34.50 (-1.80%)
     
  • Silver

    23.42
    -1.15 (-4.66%)
     
  • EUR/USD

    1.1755
    -0.0035 (-0.2939%)
     
  • 10-Yr Bond

    0.7810
    +0.0030 (+0.39%)
     
  • Vix

    40.28
    +6.93 (+20.78%)
     
  • GBP/USD

    1.2982
    -0.0060 (-0.4570%)
     
  • USD/JPY

    104.3090
    -0.1850 (-0.1770%)
     
  • BTC-USD

    13,114.86
    -86.63 (-0.66%)
     
  • CMC Crypto 200

    258.92
    -13.77 (-5.05%)
     
  • FTSE 100

    5,582.80
    -146.19 (-2.55%)
     
  • Nikkei 225

    23,418.51
    -75.79 (-0.32%)
     

Shape Therapeutics to Present Groundbreaking Advances in ADAR-Mediated RNA Editing in Parkinson’s Disease at the Jefferies Gene Therapy and Editing Summit

·1 min read

Shape Therapeutics, Inc. (ShapeTX), a pre-clinical stage company with an industry-leading RNA targeting technology platform, announced today that Francois Vigneault, PhD., President & Chief Executive Officer, will highlight advances in their RNAfix™ ADAR editing platform, including data that demonstrates RNA editing up to ~90% in genes implicated in Parkinson’s disease. The presentation will be on Friday, October 2, 2020 at 4 PM ET. The conference is being held virtually, October 1-2, 2020.

About Shape Therapeutics, Inc.

Shape Therapeutics is a biotechnology company developing next generation RNA-targeted therapies to treat the world’s most challenging diseases. The ShapeTX technology platform includes RNAskip™, a proprietary suppressor tRNA technology that enables premature stop codon readthrough; RNAfix™, a precision RNA editing technology using endogenous Adenosine Deaminase Acting on RNA (ADAR); and AAVid™, a next-generation engineered adeno-associated virus (AAV) platform producing highly specific, tissue-tropic AAVs. The power of the ShapeTX platforms resides in redirecting the cellular machinery already present in our cells, thereby bypassing the risks of immunogenicity and DNA damage seen with other contemporary editing technologies. ShapeTX is committed to data-driven scientific advancement, passionate people and a mission of providing life-long cures to patients. Shape Life!

View source version on businesswire.com: https://www.businesswire.com/news/home/20200928005719/en/

Contacts

Shape Therapeutics, Inc.
Investors & Media
John Suliman
CFO & Head of Business Strategy
John@shapetx.com